Buckysomes: New Nanocarriers for Anticancer Drugs

Area of Science:

• Nanotechnology
• Materials Science
• Pharmacology

Background:

• Buckysomes are novel liposome-like nanovectors formed from dendritic C60 subunits.
• Their self-assembly into unilamellar vesicles makes them suitable for drug encapsulation.
• Paclitaxel is a widely used chemotherapeutic agent with various delivery formulations.

Purpose of the Study:

• To prepare paclitaxel-embedded buckysomes (PEBs).
• To evaluate the biodistribution profile of PEBs.
• To compare PEBs with a commercially available paclitaxel formulation (Abraxane).

Main Methods:

• Preparation of paclitaxel-embedded buckysomes (PEBs).
• Biodistribution studies of PEBs in comparison to Abraxane.
• Analysis of drug accumulation in various organs over time.

Main Results:

• PEBs demonstrated higher tissue accumulation in the liver and kidney at 45-60 minutes post-administration.
• PEBs showed increased accumulation in the lungs at 30 minutes compared to Abraxane.
• These findings suggest PEBs as effective carriers for short-term organ-specific drug delivery.

Conclusions:

• Paclitaxel-embedded buckysomes exhibit distinct biodistribution advantages over Abraxane for specific organs.
• PEBs are suitable nanocarriers for short-term therapeutic interventions in the liver, kidney, and lungs.
• Future functionalization of buckysomes could enable targeted paclitaxel delivery to tumor sites.